Retired 84 becomes the oldest volunteer in the world to receive an injection of a coronavirus vaccine
An elderly resident of China has become the oldest volunteer in the world to receive a possible coronavirus vaccination.
Xiong Zhengxing, 84, took part in the second trial of the vaccine candidate in Wuhan along with his daughter, Xiong Ying, on Monday. They would stay healthy.
Developed by the country’s top bio-warfare expert, the vaccine is one of China’s three potential vaccinations for the deadly disease that has infected more than two million people worldwide.
All participants in the first trial remained healthy and returned home after 14 days of medical observation, the press said.
Xiong Zhengxing (center), 84, and his daughter, Xiong Ying (left), took part in the vaccine candidate’s second trial in Wuhan on Monday. They would stay healthy
The researchers recruited 500 new volunteers after starting the second trial on Sunday. At the end of Monday, 273 participants received injections, Chinese media report.
It is the first COVID-19 vaccine candidate in the world to enter the second phase of clinical trials, according to state media Xinhua.
Mr. Xiong asked to become a volunteer after his daughter, who is a pediatrician, was selected as a participant.
“I signed up for my dad after investigators told me there was no age limit,” said Ms. Xiong.
Elderly people older than 60 years were allowed to enroll in the second study after the age limit was removed. A placebo-controlled group was also introduced in the second study to evaluate the safety and effectiveness of the potential vaccine.
“It’s been more than a day [since the injections]”We are fine,” Mrs. Xiong added. “Our temperatures are normal too.”
Retired soldier Xiong Zhengxing, 84, is considered the world’s oldest volunteer for a possible coronavirus vaccine. He is shown receiving the injection
The 84-year-old retired soldier is believed to be the world’s oldest volunteer for a possible coronavirus vaccine.
“As long as it’s something for the people and the country and I’m capable, I would do it,” said the retiree Pear Video.
Chen Wei, the lead investigator, told the press that the vaccination should protect the elderly who are more susceptible to the killer beetle.
The recombinant new coronavirus vaccine was successfully developed after more than a month of research, including the study of the vaccines for Ebola.
The first clinical trial for the vaccination was given the green light in mid-March. A total of 108 healthy adults, aged between 18 and 60 years old, volunteered to receive the injections.
They were divided into three groups that were injected with different amounts of the inactivated vaccine.
All participants in the first trial completed their 14-day quarantine and returned home.
The first clinical trial for the vaccination was given the green light in mid-March. A total of 108 healthy adults, ages 18 to 60, volunteered to receive the vaccinations
‘My health has been absolutely fine during this period. I don’t feel sick or sore anywhere, ”said a participant in Pear Video when he left the facility.
“There was a slight pain in where I was injected for the first few days.
“I have a lot of confidence in the vaccine,” he added. “I think it will be presented to the public very soon.”
Another volunteer told the press that she has returned to her daily life after ‘everything feels normal’.
“It felt like getting a regular injection, like getting bitten by a mosquito,” Jin Guanping told Southern Metropolis Daily.
The research team will monitor all volunteers for another six months and take their blood samples to examine the antibodies.
Scientists said they plan to conduct additional trials abroad if the vaccine is proven to be effective and safe.
The news comes as another Beijing-based company, Sinovac Biotech, has obtained approval in China to continue a human clinical trial for its vaccine candidate on Monday.
China’s CanSino Biologics has also started the second phase of testing its candidate vaccine, the Chinese Ministry of Science and Technology said Tuesday.
This means that three potential COVID-19 vaccinations are making rapid progress in their tests in China.
Meanwhile, Oxford University scientists are convinced they can get the jab for the incurable disease that millions of people can use in the fall.
The Oxford vaccination program has already recruited 510 people between the ages of 18 and 55 to participate in the first trial.
According to the World Health Organization (WHO), more than 70 vaccines are currently under development.
The first group of Chinese volunteers to receive potential coronavirus vaccinations claimed to maintain good health after ending the two-week quarantine for observation
The recombinant new coronavirus vaccine was successfully developed after more than a month of research. Chen Wei (right) is shown with two medical researchers in Wuhan